NLRP3 and COVID-19: Statins inhibit NLRP3 inflammasome activation by suppressing the oxidized LDL, and TNF α, and improving the cardiovascular functional outcomes in COVID-19 patients (Umakanthan et al., 2021b; Koushki et al., 2021).